Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transsynaptic complex dysfunction in the hippocampus of Alzheimer's disease patients.

Frontiers in aging neuroscience·2026
Same author

Neuroscience of the premotor cortex: Implications for motivation shaping attention-motor interactions.

The Journal of physiology·2026
Same author

Interplay of Vestibular Symptoms and Intracranial Hypertension: A Diagnostic Challenge in a Patient With Tullio's Phenomenon and Elevated Intracranial Pressure.

Cureus·2025
Same author

"I was largely unguided trying to figure it out on my own": Experiences of genital tucking among transfeminine and gender diverse individuals.

International journal of transgender health·2025
Same author

Clinical trial design in FDA submissions for neuromodulation devices, 1960-2023: a systematic review and meta-analysis.

Expert review of medical devices·2025
Same author

Greater Social Isolation and Social Constraints Prior to Hematopoietic Stem Cell Transplant Are Associated with Greater Anxiety and Depressive Symptoms.

International journal of behavioral medicine·2023

Related Experiment Video

Updated: May 19, 2026

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
09:48

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice

Published on: May 4, 2015

Age-related decrease in cerebrovascular-derived neuroprotective proteins: effect of acetaminophen.

Debjani Tripathy1, Alma Sanchez, Xiangling Yin

  • 1Garrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, Texas 79430, USA.

Microvascular Research
|September 5, 2012
PubMed
Summary

Acetaminophen may help preserve brain function in aging individuals by increasing levels of vital neuroprotective proteins (VEGF, PEDF, PACAP) in brain microvessels, counteracting age-related decline and oxidative stress.

More Related Videos

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
10:13

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia

Published on: July 31, 2017

Related Experiment Videos

Last Updated: May 19, 2026

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
09:48

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice

Published on: May 4, 2015

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
10:13

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia

Published on: July 31, 2017

Area of Science:

  • Neuroscience
  • Gerontology
  • Pharmacology

Background:

  • Aging populations face increasing needs for maintaining cognitive function.
  • Co-occurrence of vascular disease and neurodegenerative disorders is common in older adults.
  • Cerebrovascular factors significantly impact neuronal viability and brain health.

Purpose of the Study:

  • To measure and compare levels of VEGF, PEDF, and PACAP in rat brain microvessels across different ages.
  • To investigate the effect of acetaminophen on the expression of these neuroprotective proteins.
  • To explore the mechanisms underlying acetaminophen's effects on endothelial cells.

Main Methods:

  • Isolated brain microvessels from Fischer 344 rats (6-24 months) were analyzed for VEGF, PEDF, and PACAP.
  • Acetaminophen was added to microvessels and cultured brain endothelial cells to assess its impact.
  • Oxidative stress was induced using menadione, and cellular responses to acetaminophen were examined.

Main Results:

  • Cerebrovascular expression of VEGF, PEDF, and PACAP significantly decreased with age.
  • Acetaminophen ameliorated the age-associated decline in VEGF and PEDF levels.
  • Acetaminophen upregulated VEGF, PEDF, and PACAP in endothelial cells under oxidative stress.

Conclusions:

  • Age-related decline in cerebrovascular neuroprotective factors is significant.
  • Acetaminophen demonstrates potential in counteracting age- and oxidative stress-induced decreases in these factors.
  • Acetaminophen may be a viable therapeutic agent for preserving cerebrovascular function and improving cognitive health in the elderly.